Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
:VRCA
VRCA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $58.20
Previous CloseN/A
Volume115.12K
Average Volume (3M)70.96K
Market Cap
$52.17M
Enterprise Value$54.78M
Total Cash (Recent Filing)$29.59M
Total Debt (Recent Filing)$42.43M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 12, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding9,250,000
10 Day Avg. Volume60,103
30 Day Avg. Volume70,957
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit10.63
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$35.00Price Target Upside520.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Commercial StrategyYcanth's commercial uptake continues to show encouraging trends that are accelerating, reflecting solid execution of VRCA's product relaunch.
Milestone PaymentsThe anticipated $10MM milestone payment upon Ycanth's approval for molluscum in Japan is expected to further strengthen VRCA's financial position.
Product DemandThe volume of dispensed Ycanth applicator units increased by approximately 33%, indicating strong product demand.
Bears Say
Financial OverhangThere is a need for significantly more sales growth to address the company's financial overhang and funding needs.
Liquidity ConcernsThe Neutral rating is maintained due to concerns about precarious liquidity in a challenging market, pending more clarity on Verrica's strategy to achieve breakeven.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.81 and its highest was $58.20 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $52.17M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Aug 12, 2025 which is in 7 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on May 13, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.262 by $0.262.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.9.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 9,250,000 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$1 in its last earnings report, beating expectations of -$1.262. Following the earnings report the stock price went down -2.727%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (520.57% Upside)
$35.00 (520.57% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 25.3%
Last 30 Days ▲ 25.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-90.41%
12-Months-Change
Fundamentals
Return on Equity
-1546.58%
Trailing 12-Months
Asset Growth
-36.39%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Verrica Pharmaceuticals' financial position, YCANTH sales growth, and clinical pipeline advancements. However, challenges such as obsolete inventory costs, suboptimal revenue figures, and financial covenant concerns were also noted. Overall, the positive developments in fundraising, sales growth, and clinical progress were prominent.Read More>VRCA Stock 12 Month Forecast
Average Price Target
$35.00
▲(520.57%Upside)
Technical Analysis
PDS Biotechnology
―
Sutro Biopharma
―
PMV Pharmaceuticals
―
Kronos Bio
―
Gain Therapeutics
―
Ownership Overview
44.85% Insiders
3.24% Mutual Funds
0.81% Other Institutional Investors
48.83% Public Companies and
Individual Investors